logo
← Back to all media

How healthcare and biotech investment trusts can revive portfolios

Healthcare and biotechnology trusts have not been immune to the stock market ravages of the coronavirus pandemic, but have fared better than others. Looking beyond the crisis, the sector will be propelled forwards by strong tailwinds, argues David Prosser.

Published on 5th May 2020

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

Disclaimer

The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the EEA.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).


I do not accept →